Cargando…
Antibody-drug conjugates—an emerging class of cancer treatment
Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated with novel highly potent cytotoxic payloads has permitted the development...
Autores principales: | Diamantis, Nikolaos, Banerji, Udai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815767/ https://www.ncbi.nlm.nih.gov/pubmed/26742008 http://dx.doi.org/10.1038/bjc.2015.435 |
Ejemplares similares
-
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
por: Staudacher, Alexander H, et al.
Publicado: (2017) -
Enhancing the Activity of Drugs by Conjugation to Organometallic Fragments
por: Chellan, Prinessa, et al.
Publicado: (2020) -
Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
por: Schizas, Dimitrios, et al.
Publicado: (2018) -
Intensity-modulated radiation therapy: emerging cancer treatment technology
por: Hong, T S, et al.
Publicado: (2005) -
Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment
por: Nishimoto, Arata
Publicado: (2022)